ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter ...
Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback